ImmuCell (NASDAQ:ICCC) Stock Passes Above Two Hundred Day Moving Average – Should You Sell?

Shares of ImmuCell Corporation (NASDAQ:ICCC) passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $6.11 and traded as high as $6.20. ImmuCell shares last traded at $6.02, with a volume of 8,934 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d+)” rating on shares of ImmuCell in a research note on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

ImmuCell Stock Down 0.3%

The firm has a 50-day moving average of $5.95 and a two-hundred day moving average of $6.11. The company has a quick ratio of 1.76, a current ratio of 4.21 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $54.48 million, a PE ratio of 23.15 and a beta of 0.18.

ImmuCell (NASDAQ:ICCC) last announced its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($0.02) EPS for the quarter. The business had revenue of $5.51 million during the quarter. ImmuCell had a net margin of 8.37% and a return on equity of 8.00%.

Institutional Trading of ImmuCell

A hedge fund recently bought a new stake in ImmuCell stock. Steadtrust LLC purchased a new position in shares of ImmuCell Corporation (NASDAQ:ICCC) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 31,700 shares of the biotechnology company’s stock, valued at approximately $198,000. Steadtrust LLC owned approximately 0.35% of ImmuCell as of its most recent SEC filing. Institutional investors and hedge funds own 13.47% of the company’s stock.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.